T1	tradename 139 146	MACUGEN
T3	tradename 212 228	MACUGEN. MACUGEN
T5	nanoparticle 232 242	pegaptanib
T7	routeofadministration 261 273	Intravitreal
T9	fdaapprovaldate 307 311	2004
T11	tradename 373 380	Macugen
T13	indication 415 465	neovascular (wet) age-related macular degeneration
T15	routeofadministration 541 553	INTRAVITREAL
T17	tradename 577 584	Macugen
T19	dose 585 591	0.3 mg
T21	frequency 615 635	once every six weeks
T23	routeofadministration 639 652	intravitreous
T25	dose 749 756	0.3 mg/
T27	routeofadministration 798 810	intravitreal
T29	adversereaction 890 921	Ocular or periocular infections
T31	adversereaction 930 946	Hypersensitivity
T33	adversereaction 1009 1024	Endophthalmitis
T35	routeofadministration 1045 1058	intravitreous
T37	tradename 1152 1160	Macugen.
T39	tradename 1322 1329	Macugen
T41	adversereaction 1352 1387	anaphylaxis/anaphylactoid reactions
T43	adversereaction 1399 1409	angioedema
T45	tradename 1605 1612	Macugen
T47	adversereaction 1639 1668	anterior chamber inflammation
T49	adversereaction 1670 1684	blurred vision
T51	adversereaction 1686 1694	cataract
T53	adversereaction 1696 1719	conjunctival hemorrhage
T55	adversereaction 1721 1734	corneal edema
T57	adversereaction 1736 1749	eye discharge
T59	adversereaction 1751 1765	eye irritation
T61	adversereaction 1767 1775	eye pain
T63	adversereaction 1777 1789	hypertension
T65	adversereaction 1791 1827	increased intraocular pressure (IOP)
T67	adversereaction 1829 1846	ocular discomfort
T69	adversereaction 1848 1866	punctate keratitis
T71	adversereaction 1868 1889	reduced visual acuity
T73	adversereaction 1891 1909	visual disturbance
T75	adversereaction 1911 1928	vitreous floaters
T77	adversereaction 1934 1952	vitreous opacities
T79	company 2008 2020	Eyetech Inc.
T81	tradename 2030 2037	MACUGEN
T83	adversereaction 2500 2515	Endophthalmitis
T85	adversereaction 2521 2554	Increases in Intraocular Pressure
T87	tradename 3243 3250	Macugen
T89	indication 3285 3322	neovascular (wet) age-related macular
T91	routeofadministration 3415 3427	INTRAVITREAL
T93	tradename 3456 3463	Macugen
T95	dose 3464 3470	0.3 mg
T97	frequency 3494 3514	once every six weeks
T99	routeofadministration 3518 3531	intravitreous
T101	tradename 3606 3613	Macugen
T103	routeofadministration 5827 5839	intravitreal
T105	adversereaction 5968 6001	elevation in intraocular pressure
T107	adversereaction 6010 6026	endophthalmitis.
T109	adversereaction 6312 6327	endophthalmitis
T111	tradename 6489 6496	Macugen
T113	dose 6641 6647	0.3 mg
T115	tradename 6651 6658	Macugen
T117	routeofadministration 6690 6702	intravitreal
T119	tradename 6773 6780	Macugen
T121	tradename 6875 6882	Macugen
T123	nanoparticle 6945 6955	pegaptanib
T125	adversereaction 7037 7052	Endophthalmitis
T127	routeofadministration 7054 7067	Intravitreous
T129	tradename 7101 7108	Macugen
T131	adversereaction 7136 7152	endophthalmitis.
T133	tradename 7235 7243	Macugen.
T135	adversereaction 7425 7458	Increases in Intraocular Pressure
T137	adversereaction 7460 7493	Increases in intraocular pressure
T139	tradename 7545 7553	Macugen.
T141	adversereaction 7727 7738	Anaphylaxis
T143	adversereaction 7754 7789	anaphylaxis/anaphylactoid reactions
T145	adversereaction 7801 7811	angioedema
T147	tradename 7879 7886	Macugen
T149	routeofadministration 7887 7899	intravitreal
T151	routeofadministration 8119 8132	intravitreous
T153	adversereaction 8153 8168	endophthalmitis
T155	adversereaction 8207 8225	retinal detachment
T157	adversereaction 8231 8261	iatrogenic traumatic cataract.
T159	tradename 8365 8372	Macugen
T161	dose 8373 8379	0.3 mg
T163	adversereaction 8405 8434	anterior chamber inflammation
T165	adversereaction 8436 8450	blurred vision
T167	adversereaction 8452 8460	cataract
T169	adversereaction 8462 8485	conjunctival hemorrhage
T171	adversereaction 8487 8500	corneal edema
T173	adversereaction 8502 8515	eye discharge
T175	adversereaction 8517 8531	eye irritation
T177	adversereaction 8533 8541	eye pain
T179	adversereaction 8543 8555	hypertension
T181	adversereaction 8557 8593	increased intraocular pressure (IOP)
T183	adversereaction 8595 8612	ocular discomfort
T185	adversereaction 8614 8632	punctate keratitis
T187	adversereaction 8634 8655	reduced visual acuity
T189	adversereaction 8657 8675	visual disturbance
T191	adversereaction 8677 8694	vitreous floaters
T193	adversereaction 8700 8719	vitreous opacities.
T195	tradename 8848 8855	Macugen
T197	dose 8856 8862	0.3 mg
T199	adversereaction 8881 8892	blepharitis
T201	adversereaction 8894 8908	conjunctivitis
T203	adversereaction 8910 8919	photopsia
T205	adversereaction 8921 8939	vitreous disorder.
T207	adversereaction 8954 8964	bronchitis
T209	adversereaction 8966 8974	diarrhea
T211	adversereaction 8976 8985	dizziness
T213	adversereaction 8987 8995	headache
T215	adversereaction 8997 9003	nausea
T217	adversereaction 9005 9029	urinary tract infection.
T219	tradename 9096 9103	Macugen
T221	dose 9104 9110	0.3 mg
T223	adversereaction 9130 9153	allergic conjunctivitis
T225	adversereaction 9155 9173	conjunctival edema
T227	adversereaction 9175 9191	corneal abrasion
T229	adversereaction 9193 9209	corneal deposits
T231	adversereaction 9211 9238	corneal epithelium disorder
T233	adversereaction 9240 9255	endophthalmitis
T235	adversereaction 9257 9273	eye inflammation
T237	adversereaction 9275 9287	eye swelling
T239	adversereaction 9289 9306	eyelid irritation
T241	adversereaction 9308 9321	meibomianitis
T243	adversereaction 9323 9332	mydriasis
T245	adversereaction 9334 9354	periorbital hematoma
T247	adversereaction 9356 9369	retinal edema
T249	adversereaction 9371 9391	vitreous hemorrhage.
T251	adversereaction 9406 9415	arthritis
T253	adversereaction 9417 9426	bone spur
T255	adversereaction 9428 9452	carotid artery occlusion
T257	adversereaction 9454 9478	cerebrovascular accident
T259	adversereaction 9480 9490	chest pain
T261	adversereaction 9492 9510	contact dermatitis
T263	adversereaction 9512 9521	contusion
T265	adversereaction 9523 9540	diabetes mellitus
T267	adversereaction 9542 9551	dyspepsia
T269	adversereaction 9553 9565	hearing loss
T271	adversereaction 9567 9583	pleural effusion
T273	adversereaction 9585 9610	transient ischemic attack
T275	adversereaction 9612 9629	urinary retention
T277	adversereaction 9631 9638	vertigo
T279	adversereaction 9640 9649	vomiting.
T281	adversereaction 9681 9716	Anaphylaxis/anaphylactoid reactions
T283	adversereaction 9728 9738	angioedema
T285	tradename 9788 9796	Macugen.
T287	nanoparticle 10166 10176	Pegaptanib
T289	routeofadministration 10271 10282	intravenous
T291	dose 10298 10306	40 mg/kg
T293	frequency 10306 10310	/day
T295	dose 10381 10388	0.3 mg/
T297	nanoparticle 10395 10405	Pegaptanib
T299	nanoparticle 10710 10720	pegaptanib
T301	tradename 10829 10836	Macugen
T303	tradename 10920 10927	Macugen
T305	tradename 11053 11060	Macugen
T307	tradename 11249 11256	Macugen
T309	dose 11298 11304	0.3 mg
T311	dose 11419 11424	1 mg.
T313	tradename 11442 11449	Macugen
T315	nanoparticle 11451 11461	pegaptanib
T317	nanoparticle 11522 11532	pegaptanib
T319	routeofadministration 11544 11557	intravitreous
T321	tradename 11571 11578	Macugen
T323	activeingredient 11710 11726	oligonucleotide.
T325	dose 11752 11758	0.3 mg
T327	activeingredient 11788 11803	oligonucleotide
T329	surfacecoating 11812 11831	polyethylene glycol
T331	nanoparticle 11901 11911	pegaptanib
T333	surfacecoating 11920 11929	pegylated
T335	activeingredient 11930 11946	oligonucleotide)
T337	activeingredient 12004 12019	oligonucleotide
T339	inactiveingredient 12101 12116	sodium chloride
T341	inactiveingredient 12118 12156	monobasic sodium phosphate monohydrate
T343	inactiveingredient 12158 12195	dibasic sodium phosphate heptahydrate
T345	inactiveingredient 12197 12214	hydrochloric acid
T347	inactiveingredient 12223 12239	sodium hydroxide
T349	nanoparticle 12283 12293	Pegaptanib
T351	activeingredient 12331 12374	oligonucleotide of twenty-eight nucleotides
T353	molecularweight 12439 12452	20-kilodalton
T355	surfacecoating 12453 12490	monomethoxy polyethylene glycol (PEG)
T357	nanoparticle 12568 12578	Pegaptanib
T359	nanoparticle 12702 12712	pegaptanib
T361	nanoparticle 13279 13289	pegaptanib
T363	molecularweight 13408 13423	50 kilodaltons.
T365	tradename 13426 13433	Macugen
T367	nanoparticle 13560 13570	Pegaptanib
T369	indication 13931 13989	neovascular (wet) form of age-related macular degeneration
T371	nanoparticle 14133 14143	Pegaptanib
T373	surfacecoating 14161 14170	pegylated
T375	activeingredient 14180 14195	oligonucleotide
T377	nanoparticle 14327 14337	pegaptanib
T379	nanoparticle 14646 14656	pegaptanib
T381	routeofadministration 14725 14738	intravitreous
T383	nanoparticle 14841 14851	pegaptanib
T385	cmax 14975 14983	80 ng/mL
T387	tmax 14998 15009	1 to 4 days
T389	dose 15018 15022	3 mg
T391	auc 15144 15158	25 hr/mL
T393	nanoparticle 15174 15184	Pegaptanib
T395	tradename 15337 15344	Macugen
T397	nanoparticle 15468 15479	pegaptanib.
T399	routeofadministration 15541 15554	intravitreous
T401	nanoparticle 15596 15606	pegaptanib
T403	routeofadministration 15722 15735	intravitreous
T405	routeofadministration 15740 15751	intravenous
T407	nanoparticle 15784 15794	pegaptanib
T409	routeofadministration 15878 15891	intravitreous
T411	nanoparticle 16039 16049	pegaptanib
T413	routeofadministration 16050 16061	intravenous
T415	routeofadministration 16066 16079	intravitreous
T417	nanoparticle 16100 16110	pegaptanib
T419	nanoparticle 16208 16218	pegaptanib
T421	dose 16281 16285	3 mg
T423	nanoparticle 16397 16407	pegaptanib
T425	plasmahalflife 16411 16423	10 (4) days.
T427	nanoparticle 16689 16699	pegaptanib
T429	nanoparticle 16848 16858	Pegaptanib
T431	nanoparticle 17012 17022	Pegaptanib
T433	nanoparticle 17363 17373	Pegaptanib
T435	tradename 17462 17469	Macugen
T437	indication 17577 17593	neovascular AMD.
T439	dose 17660 17666	0.3 mg
T441	dose 17668 17672	1 mg
T443	dose 17676 17680	3 mg
T445	tradename 17681 17688	Macugen
T447	routeofadministration 17705 17718	intravitreous
T449	tradename 17841 17848	Macugen
T451	indication 18278 18293	neovascular AMD
T453	tradename 18746 18753	Macugen
T455	dose 18754 18760	0.3 mg
T457	tradename 18881 18888	Macugen
T459	tradename 18922 18929	Macugen
T461	tradename 19044 19051	Macugen
T463	dose 19052 19058	0.3 mg
T465	tradename 19099 19106	Macugen
T467	dose 19107 19113	0.3 mg
T469	tradename 19239 19246	Macugen
T471	tradename 19599 19606	Macugen
T473	tradename 19780 19787	Macugen
T475	tradename 19834 19841	Macugen
T477	dose 19921 19927	0.3 mg
T479	tradename 20000 20007	Macugen
T481	tradename 20090 20097	Macugen
T483	nanoparticle 20099 20109	pegaptanib
T485	dose 20210 20216	0.3 mg
T487	tradename 20220 20227	Macugen
T489	tradename 20613 20620	Macugen
T491	tradename 20893 20902	MACUGEN (
T493	nanoparticle 20902 20912	pegaptanib
T495	company 20951 20966	Gilead Sciences
T497	company 20968 20971	Inc
T499	company 21022 21034	Eyetech Inc.
T501	company 21159 21184	Becton Dickinson &amp; CO
